» Articles » PMID: 20459733

Evaluation of 'see-see and Treat' Strategy and Role of HIV on Cervical Cancer Prevention in Uganda

Overview
Journal Reprod Health
Publisher Biomed Central
Date 2010 May 13
PMID 20459733
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background: There is scant information on whether Human Immunodeficiency Virus (HIV) seropositivity has an influence on the outcome of treatment of precancerous cervical lesions using cryotherapy. We studied the prevalence of cervical abnormalities detectable by visual inspection and cervical lesions diagnosed by colposcopy according to HIV serostatus and described the outcomes of cryotherapy treatment.

Methods: Trained nurses examined women not previously screened for cervical cancer using visual inspection with acetic acid (VIA) and Lugol's iodine (VILI) in two family planning/post natal clinics in Kampala, Uganda, from February 2007 to August 2008. Women with abnormal visual inspection findings were referred for colposcopic evaluation and HIV testing. Women with precancerous cervical lesions detected at colposcopy were treated mainly by cryotherapy, and were evaluated for treatment outcome after 3 months by a second colposcopy.

Results: Of the 5 105 women screened, 834 presented a positive screening test and were referred for colposcopy. Of these 625 (75%) returned for the colposcopic evaluation and were tested for HIV. For the 608 (97.5%) women in the age range 20-60 years, colposcopy revealed 169 women with cervical lesions: 128 had inflammation, 19 had low grade squamous intraepithelial lesion (LGSIL), 13 had high grade squamous intraepithelial lesion (HGSIL), 9 had invasive cervical cancer and 2 had inconclusive findings. Detection rates per 1 000 women screened were higher among the older women (41-60 years) compared to women aged 20-40 years. They were accordingly 55% and 20% for inflammation, 10% and 2% for LGSIL, 5% and 2% for HGSIL, 6% and 1% for invasive cervical cancer.Of the 608 women, 103 (16%) were HIV positive. HIV positivity was associated with higher likelihood of inflammation (RR = 1.7; 95% CI: 1.2-2.4).

Conclusions: Detection rates were higher among older women 41-60 years. Visual inspection of the cervix uteri with acetic acid (VIA) and Lugol's iodine (VILI) used as a sole method for cervical cancer screening would entail significant false positive results. HIV seropositivity was associated with a higher prevalence of inflammatory cervical lesions. In view of the small numbers and the relatively short follow up time of 3 months, we could not make an emphatic conclusion about the effect of HIV serostatus on cryotherapy treatment outcome.

Citing Articles

A Framework for Cervical Cancer Elimination in Low-and-Middle-Income Countries: A Scoping Review and Roadmap for Interventions and Research Priorities.

Shin M, Liu G, Mugo N, Garcia P, Rao D, Broshkevitch C Front Public Health. 2021; 9:670032.

PMID: 34277540 PMC: 8281011. DOI: 10.3389/fpubh.2021.670032.


Visual inspection with acetic acid (VIA) positivity among female sex workers: a cross-sectional study highlighting one-year experiences in early detection of pre-cancerous and cancerous cervical lesions in Kampala, Uganda.

Namale G, Mayanja Y, Kamacooko O, Bagiire D, Ssali A, Seeley J Infect Agent Cancer. 2021; 16(1):31.

PMID: 33975633 PMC: 8114699. DOI: 10.1186/s13027-021-00373-4.


Cervical Cancer Screening in HIV-Positive Farmers in South Africa: Mixed-Method Assessment.

Lieber M, Afzal O, Shaia K, Mandelberger A, Du Preez C, Beddoe A Ann Glob Health. 2019; 85(1).

PMID: 30993957 PMC: 6634387. DOI: 10.5334/aogh.37.


Prevention of cervical cancer in HIV-seropositive women from developing countries through cervical cancer screening: a systematic review.

Mapanga W, Girdler-Brown B, Feresu S, Chipato T, Singh E Syst Rev. 2018; 7(1):198.

PMID: 30447695 PMC: 6240280. DOI: 10.1186/s13643-018-0874-7.


Acceptability of cervical cancer screening using visual inspection among women attending a childhood immunization clinic in Uganda.

Li M, Nyabigambo A, Navvuga P, Nuwamanya E, Nuwasiima A, Kaganda P Papillomavirus Res. 2017; 4:17-21.

PMID: 29179864 PMC: 5883247. DOI: 10.1016/j.pvr.2017.06.004.


References
1.
Cardenas-Turanzas M, Follen M, Benedet J, Cantor S . See-and-treat strategy for diagnosis and management of cervical squamous intraepithelial lesions. Lancet Oncol. 2005; 6(1):43-50. DOI: 10.1016/S1470-2045(04)01712-7. View

2.
Sarkar A, Tortolero-Luna G, Follen M, Sastry K . Inverse correlation of cellular immune responses specific to synthetic peptides from the E6 and E7 oncoproteins of HPV-16 with recurrence of cervical intraepithelial neoplasia in a cross-sectional study. Gynecol Oncol. 2005; 99(3 Suppl 1):S251-61. DOI: 10.1016/j.ygyno.2005.07.099. View

3.
Einstein M, Schiller J, Viscidi R, Strickler H, Coursaget P, Tan T . Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis. 2009; 9(6):347-56. DOI: 10.1016/S1473-3099(09)70108-2. View

4.
Hemminki K, Li X, Vaittinen P . Time trends in the incidence of cervical and other genital squamous cell carcinomas and adenocarcinomas in Sweden, 1958-1996. Eur J Obstet Gynecol Reprod Biol. 2002; 101(1):64-9. DOI: 10.1016/s0301-2115(01)00508-5. View

5.
ter Meulen J, Eberhardt H, Luande J, Mgaya H, Chang-Claude J, Mtiro H . Human papillomavirus (HPV) infection, HIV infection and cervical cancer in Tanzania, east Africa. Int J Cancer. 1992; 51(4):515-21. DOI: 10.1002/ijc.2910510403. View